United Therapeutics (UTHR) Tops Q2 EPS by $1.07
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $498.65 +2.26%
EPS Growth %: -10.1%
Financial Fact:
Other, net: 1M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -10.1%
Financial Fact:
Other, net: 1M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $4.09, $1.07 better than the analyst estimate of $3.02. Revenue for the quarter came in at $446.5 million versus the consensus estimate of $378.75 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- BMO Capital Reiterates Outperform Rating on NVIDIA (NVDA)
- MSC Industrial names Rob Kuhns as executive VP and CFO
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
